Related Experiment Video
Updated: Apr 28, 2026

05:58
Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
3.8K
[Comparative study of medical device classification between China and USA]
Summary
This study compares medical device classification in China and the USA, identifying issues within China's system. Recommendations are proposed to enhance China's medical device regulations by referencing the US approach.
Area of Science:
- Regulatory Science
- Health Policy
Background:
- Medical device classification is crucial for ensuring product safety and efficacy.
- Existing regulatory frameworks vary significantly across different countries.
- China's medical device classification system has undergone revisions to align with international standards.
Purpose of the Study:
- To compare the medical device classification systems of China and the USA.
- To identify inherent challenges and limitations within China's current classification framework.
- To propose actionable recommendations for improving China's medical device regulatory system.
Main Methods:
- Comparative analysis of the regulatory structures and classification criteria for medical devices in China and the USA.
- Review of relevant national regulations and guidelines from both countries.
- Identification of discrepancies and areas for improvement in the Chinese system.
Main Results:
- Significant differences were observed in the classification principles, risk-based approaches, and nomenclature between the Chinese and US systems.
- Several critical issues were identified in China's classification system, including ambiguity in certain categories and lack of harmonization with international standards.
- The US system demonstrates a more robust and detailed risk-based classification approach.
Conclusions:
- China's medical device classification system requires further refinement to enhance regulatory clarity and international alignment.
- Adopting principles from the US classification system can address identified shortcomings and strengthen China's regulatory oversight.
- Harmonization efforts are essential for facilitating global trade and ensuring consistent patient safety.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430

